No Data
Dezhan Healthcare (000813.SZ): Wuhan Weili Kang has obtained the Medical institution practice license.
Gelonghui, January 2nd | Dezhan Healthcare (000813.SZ) announced that to further promote the in-depth development of the Medical and Healthcare Sector of Dezhan Health Co., Ltd. and to create new business growth points, the company's wholly-owned subsidiary Hainan Dezhan Health Medical Co., Ltd. signed a relevant agreement with Shenzhen Weili Kang Medical Management Co., Ltd. in February 2024 to jointly invest in the establishment of Wuhan Weili Kang Medical Management Co., Ltd. (hereinafter referred to as "Wuhan Weili Kang"), to invest in and construct the Wuhan Psychological Rehabilitation Hospital project, aiming to create a tertiary standard specialty hospital for mental rehabilitation. Recently, Wuhan Weili Kang obtained approval from the Hubei Provincial Health Commission.
Dezhan Healthcare (000813.SZ): has repurchased a total of 1.32% of its shares.
On January 2, Gelonghui reported that Dezhan Healthcare (000813.SZ) announced that as of December 31, 2024, the company has cumulatively repurchased 28,567,500 shares through a dedicated securities account for share repurchase via centralized bidding trade, accounting for 1.32% of the company's current total share capital, with a highest Fill Price of 3.21 yuan/share, a lowest Fill Price of 2.39 yuan/share, and a total amount of 73.2659 million yuan (excluding transaction fees).
Dezhan Healthcare Ties Up With CAE's Academician Yang Baofeng to Set Up Drug-Developing Workstation
Dezhan Healthcare (000813.SZ): Signed a cooperation framework agreement with Academician Yang Baofeng from the Chinese Academy of Engineering.
On December 18, Gelonghui announced that Dezhan Healthcare (000813.SZ) has been established to further enhance the research and innovation capabilities of Dezhan Healthcare Co., Ltd. (hereinafter referred to as "the company"), build a high-level research and innovation system, improve the efficiency of research and innovation, accelerate the conversion of technological achievements, and provide strong intellectual support and technical guarantee for the sustainable development of the company. On December 17, 2024, the company signed a "Cooperation Framework Agreement" with Academician Yang Baofeng from the Chinese Academy of Engineering to jointly conduct research and development of pharmaceuticals and health products in various fields such as cardiovascular and cerebrovascular diseases, cancer, metabolic system diseases, pulmonary hypertension, and neurological and mental disorders.
Dezhan Healthcare Company Limited (SZSE:000813) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
dezhan healthcare (000813.SZ): Shanghai Yueye's 19.13% stake in the company is planned to be auctioned.
Dezhan Healthcare (000813.SZ) issued an announcement that the company received shares held at 5... on November 27, 2024.
Further Weakness as Dezhan Healthcare (SZSE:000813) Drops 6.1% This Week, Taking Five-year Losses to 63%
No Data
